H.R. 6393 · 116th Congress
Strengthening America’s Supply Chain and National Security Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
WaltzSponsor15 cosponsors · 3 D, 12 R
D
McGovern
DB
R
Bacon
MG
R
Gaetz
DH
D
Haaland
EL
D
Luria
BM
R
Mast
DR
R
Riggleman
WS
R
Steube
WT
R
Timmons
RW
R
Wright
BP
R
Posey
ST
R
Tipton
RS
R
Spano
JG
R
González-Colón
JB
R
Baird1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Strengthening America's Supply Chain and National Security Act
What it does: CRS summary · Introduced in House · Mar 25, 2020
Strengthening America's Supply Chain and National Security Act
This bill requires the Department of Defense (DOD) and the Department of Health and Human Services (HHS) to take specified actions concerning the importation of pharmaceutical products from China and any other countries selected by DOD.
DOD must submit to Congress a classified report that addresses, among other issues, the percentage of pharmaceutical products used by DOD that are made by such countries and recommendations related to the domestic manufacturing capacity and the resiliency of the supply chain for such products. An unclassified summary of this report must be published on a DOD website.
A manufacturer of a pharmaceutical product that has received market approval must annually submit to HHS specified information about the product's active and inactive pharmaceutical ingredients, including the sources of such ingredients and the percentage of the aggregate amount of such ingredients from China and other countries selected by DOD. HHS shall provide such information to DOD.
In addition, the bill revises certain statutory tests used to determine the country of origin of a pharmaceutical product. Specifically, a pharmaceutical product shall be deemed to have the same country of origin as the product's active pharmaceutical ingredient (API). (A recent court case held that a drug manufactured in the United States using an API from India is considered a U.S.-made product for procurement purposes.)
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Strengthening America’s Supply Chain and National Security Act
Latest action (Mar 25, 2020): Referred to the Subcommittee on Trade.
Policy area: Health · Origin: House · Introduced: Mar 25, 2020
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.